

October 15, 2015

Subjects:

- **Fee schedule changes for 2016**
- **Individualized consultation**
- **PCR testing updates**

Dear Client:

Thank you for your continuing confidence in our laboratory. Our lab was founded in 1962 and continues to be the reference center for toxoplasmosis in the United States and the world over. We take this task with the moral responsibility it brings and continuously strive to operate with the highest standards in laboratory medicine. We have an active exchange program of blind samples with several European laboratories and have consistently achieved 100% sensitivity and specificity in these exchanges. Please take a moment to review the following as 2015 comes to an end:

Fee schedule effective January 15, 2016 (Please see attached document)

In order to continue to provide our clients with the high level of diagnostic testing and consultation services, we will implement a small but necessary overall increase in our fees. We remain a **not for profit** institution and had not raised our fees for 3 years. For this reason our price increase is solely designed to cover increasing costs.

Individualized consultation

We continue to provide individualized consultations on results interpretations and patient management at no additional charge on each patient as needed or requested by our clients. With prior arrangements, our medical consultants are available 24 hours every day, seven days a week for laboratory and medical advice.


PCR Testing


As we strive to provide the highest quality service for the detection of *Toxoplasma gondii* DNA by the polymerase chain reaction (PCR) test, we have participated for the past 4 years in an international proficiency testing program (QCMD) with other respected labs from across Europe and the world. Our test results have demonstrated 100% specificity and sensitivity in the assessment every year, even for samples with low levels of *Toxoplasma* DNA.


Although these results support the high performance level of our current PCR test, we seek to continually improve our tests. We have validated a new PCR target that has been reported to have superior sensitivity by European labs (*Reisch, U., et al. Comparison of two DNA targets for the diagnosis of Toxoplasmosis by real-time PCR using fluorescence resonance energy transfer hybridization probes. BMC Infectious Diseases 3:7, May 2003*). We plan to implement use of this target in our PCR test early in 2016.

We look forward to continuing to serve you in the coming years, and to providing you with tools to optimize patient care through services offered at the Toxoplasma Serology Laboratory.

Sincerely,


Jose G. Montoya, M.D., FAAP, FIDSA
Laboratory Director


Cindy Press, MLS (ASCP)
Laboratory Manager


Ian J. Selsky, MS-HCA
Administrative Manager